Metabolic Tumor Volume Predicts Disease Progression and Survival in Patients with Squamous Cell Carcinoma of the Anal Canal

被引:48
作者
Bazan, Jose G.
Koong, Albert C.
Kapp, Daniel S.
Quon, Andrew [2 ]
Graves, Edward E.
Loo, Billy W., Jr.
Chang, Daniel T. [1 ]
机构
[1] Stanford Univ, Med Ctr, Dept Radiat Oncol, Stanford, CA 94305 USA
[2] Stanford Univ, Div Nucl Med, Dept Radiol, Stanford, CA 94305 USA
关键词
PET; metabolic tumor volume; anal cancer; IMRT; SUV; EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; POSITRON-EMISSION; RANDOMIZED-TRIAL; LUNG-CANCER; NECK CANCER; FDG-PET/CT; RADIOTHERAPY; MITOMYCIN; FLUOROURACIL; INTERGROUP;
D O I
10.2967/jnumed.112.109470
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PET imaging has become a useful diagnostic tool in patients with anal cancer. We evaluated the prognostic value of metabolic tumor volume (MTV) in patients with anal cancer treated with definitive chemoradiotherapy. Methods: Patients with anal cancer who underwent PET imaging for pretreatment staging or radiation therapy planning from 2003 to 2011 were included. PET parameters included MTV and maximum standardized uptake value (SUVmax). Total MTV (MTV-T) was defined as the sum of the volumes above a standardized uptake value 50% of the SUVmax within the primary tumor and involved nodes. Kaplan-Meier and Cox regression models were used to test for associations between metabolic or clinical endpoints and overall survival (OS), progression-free survival (PFS), and event-free survival (EFS). Results: Thirty-nine patients were included. Median follow-up for the cohort was 22 mo. Overall, 6 patients died and 9 patients had disease progression. The 2-y OS, PFS, and EFS for the entire cohort were 88%, 74%, and 69%, respectively. Higher MTV-T was associated with worse OS (P = 0.04), PFS (P = 0.004), and EFS (P = 0.002) on univariate analysis. Patients with an MTV greater than 26 cm(3) had worse PFS than did those with an MTV of 26 cm(3) or less (33% vs. 82%, P = 0.003). SUVmax was not prognostic for any outcome. Higher T classification (T3/T4 vs. T1/T2) was associated with worse PFS and EFS. When adjusting for T classification, MTV-T remained a significant predictor for PFS (P = 0.01) and EFS (P = 0.02). Conclusion: MTV-T yields prognostic information on PFS and EFS beyond that of established prognostic factors in patients with anal cancer.
引用
收藏
页码:27 / 32
页数:6
相关论文
共 23 条
[1]   Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal - A randomized controlled trial [J].
Ajani, Jaffer A. ;
Winter, Kathryn A. ;
Gunderson, Leonard L. ;
Pedersen, John ;
Benson, Al B., III ;
Thomas, Charles R., Jr. ;
Mayer, Robert J. ;
Haddock, Michael G. ;
Rich, Tyvin A. ;
Willett, Christopher .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (16) :1914-1921
[2]   Prognostic Factors Derived from A Prospective Database Dictate Clinical Biology of Anal Cancer The Intergroup Trial (RTOG 98-11) [J].
Ajani, Jaffer A. ;
Winter, Kathryn A. ;
Gunderson, Leonard L. ;
Pedersen, John ;
Benson, Al B., III ;
Thomas, Charles R., Jr. ;
Mayer, Robert J. ;
Haddock, Michael G. ;
Rich, Tyvin A. ;
Willett, Christopher G. .
CANCER, 2010, 116 (17) :4007-4013
[3]   CONTRAST-ENHANCED [18F]FLUORODEOXYGLUCOSE-POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY FOR STAGING AND RADIOTHERAPY PLANNING IN PATIENTS WITH ANAL CANCER [J].
Bannas, Peter ;
Weber, Christoph ;
Adam, Gerhard ;
Frenzel, Thorsten ;
Derlin, Thorsten ;
Mester, Janos ;
Klutmann, Susanne .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02) :445-451
[4]   Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups [J].
Bartelink, H ;
Roelofsen, F ;
Eschwege, F ;
Rougier, P ;
Bosset, JF ;
Gonzalez, DG ;
Peiffert, D ;
vanGlabbeke, M ;
Pierart, M .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2040-2049
[5]   Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal [J].
Bazan, Jose G. ;
Hara, Wendy ;
Hsu, Annie ;
Kunz, Pamela A. ;
Ford, James ;
Fisher, George A. ;
Welton, Mark L. ;
Shelton, Andrew ;
Kapp, Daniel S. ;
Koong, Albert C. ;
Goodman, Karyn A. ;
Chang, Daniel T. .
CANCER, 2011, 117 (15) :3342-3351
[6]   Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT):: A feasibility study [J].
Ciernik, IF ;
Dizendorf, E ;
Baumert, BG ;
Reiner, B ;
Burger, C ;
Davis, JB ;
Lütolf, UM ;
Steinert, HC ;
Von Schulthess, GK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (03) :853-863
[7]   FDG-PET/CT in the evaluation of anal carcinoma [J].
Cotter, Shane E. ;
Grigsby, Perry W. ;
Siegel, Barry A. ;
Dehdashti, Farrokh ;
Malyapa, Robert S. ;
Fleshman, James W. ;
Birnbaum, Elisa H. ;
Wang, Xia ;
Abbey, Elliot ;
Tan, Benjamin ;
Kodner, Ira J. ;
Hunt, Steven R. ;
Lowney, Jennifer K. ;
Mutch, Matthew G. ;
Dietz, David W. ;
Myerson, Robert J. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (03) :720-725
[8]   FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy [J].
Day, F. L. ;
Link, E. ;
Ngan, S. ;
Leong, T. ;
Moodie, K. ;
Lynch, C. ;
Michael, M. ;
de Winton, E. ;
Hogg, A. ;
Hicks, R. J. ;
Heriot, A. .
BRITISH JOURNAL OF CANCER, 2011, 105 (04) :498-504
[9]   18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging [J].
Dibble, Elizabeth H. ;
Alvarez, Ana C. Lara ;
Minh-Tam Truong ;
Mercier, Gustavo ;
Cook, Earl F. ;
Subramaniam, Rathan M. .
JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (05) :709-715
[10]   Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study [J].
Flam, M ;
John, M ;
Pajak, TF ;
Petrelli, N ;
Myerson, R ;
Doggett, S ;
Quivey, J ;
Rotman, M ;
Kerman, H ;
Coia, L ;
Murray, K .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) :2527-2539